-The Hindu Business Line After the 1980s, special interest groups have preferred to knock on the doors of the judiciary. In India today, matters of public interest seem to get their due only when the Supreme Court has added its two cents. Interest groups, representing both general and special interests, petition the judiciary actively. In an era where virtually all institutions in India have been vulnerable to political capture, the judiciary seems like...

-The Times of India The broad consensus finally reached by major political parties on the land acquisition Bill is a major breakthrough. The Bill, if passed, will bring transparency to the land acquisition process, help clear investor uncertainty and hopefully improve the supply of land for development. The break in the stalemate was made possible by a flexible approach of the government, which incorporated proposals of opposition parties. This is a...

-The Hindu   "Stopping rape" isn't possible unless we change the way we tackle and think about ordinary violence Some images stay branded on your mind. The brutality visited on three young girls, before their bodies were found in a well; the pain of a five-year-old whose rapist used candles and an oil bottle to violate her further; the anger of the Dalit rape survivor in Uttar Pradesh who was told by a...

-The Hindu Business Line Kolkata: Everyone knew that the bomb was ticking. But, there was not much action to curb the mushrooming ponzi schemes that were collecting thousands of crores from hapless investors across West Bengal since 2007-08. Some promised to grow money by 34 times in 25 years by investing in teak bonds. Others offered to double money in 15 months by investing in the potato trade. As a result, investments...

-The Times of India JAIPUR: In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) free of cost to them. The government's decision follows the April 1 Supreme Court decision to dismiss Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec (Imatinib). Currently the tablet is sold in the market by Novartis at...